Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT06839469 · Columbia University

Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders

What this study is about

The purpose of this research is (1) to identify disease specific walking-related digital biomarkers of disease severity, and (2) monitor longitudinal changes in natural environments, for extended periods of time, in DMD and SMA.

View original scientific description

The purpose of this research is (1) to identify disease specific walking-related digital biomarkers of disease severity, and (2) monitor longitudinal changes in natural environments, for extended periods of time, in DMD and SMA.

Primary outcome measures

Six Minute Walk Test

Time frame: One day

Participants will complete the six minute walk test in a corridor which includes the instrumented walkway, while wearing the insoles. This is to measure spatial parameters, kinetic parameters, temporal parameters, and metrics of cumulative activity in order to compare against the gold standard instrumented walkway. The six minute walk test is an objective evaluation of functional exercise capacity, and measures the maximum distance a person can walk in six minutes over a 25 meter course.

10 Meter Walk/Run

Time frame: One day

Participants will walk, or run if able to, for 10 meters on the instrumented walkway while also wearing the insoles. This will be done to measure spatial parameters, kinetic parameters, temporal parameters, and metrics of cumulative activity in order to compare against the gold standard instrumented walkway. This outcome is reported as the time it takes for the participant to complete 10 meters as fast as possible.

Time Up and Go Test (TUG)

Time frame: One day

Participants will complete the TUG test. This is a timed test of mobility, requiring the participant to stand up from a seated position, walk 3 meters and return to sitting in the chair. The outcome reported is the time it takes for the participant to complete the sequence.

Muscle Strength Testing with Hand-held Dynamometry (HHD)

Time frame: One day

HHD is used to assess the strength of muscles and is reported as the maximum strength exerted in pounds (lbs).

30 Second Sit to Stand Test (30STS)

Time frame: One day

30STS test is used to basic muscle power and function. The participant begins seated with their arms at their sides, feet flat on the floor and back against the chair. They are instructed to rise up to a full standing position and sit back down as many times as possible in 30 seconds, with or without using their hands for support.

Ankle Range of Motion

Time frame: One day

Ankle range of motion (ROM) will be assessed on both the left right side using standardized goniometers. The procedures used will be standardized and performed by trained physical therapists who have attended in-person training. ROM will be recorded in degrees for plantar flexion and dorsiflexion.

Knee Extension Range of Motion

Time frame: One day

Knee extension range of motion (ROM) will be assessed on both the left right side using standardized goniometers. The procedures used will be standardized and performed by trained physical therapists who have attended in-person training. ROM will be recorded in degrees of knee extension.

Hip Extension Range of Motion

Time frame: One day

Hip extension range of motion (ROM) will be assessed on both the left right side using standardized goniometers. The procedures used will be standardized and performed by trained physical therapists who have attended in-person training. ROM will be recorded in degrees of hip extension.

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • Genetic confirmation of disease (DMD, SMA) or healthy control
  • Able to walk independently at least 25 meters
  • Ongoing corticosteroids therapy or initiation of corticosteroid therapy in the previous 3 months for DMD
  • Stable dose of FDA approved SMN up-regulator therapy or in an open-label extension phase of a study treatment for at least 6 months for SMA or gene replacement at enrollment for SMA or DMD participants.

Exclusion criteria

  • Use foot orthoses or assistive devices for community ambulation or a mobility device for community navigation
  • Use investigational medications intended for treatment of NMD within 30 days
  • Prior to study entry had an injury or surgery that would impact gait within the previous 3 months

Where

  • Palo Alto, California
  • Boston, Massachusetts
  • New York, New York

Collaborators

Stevens Institute of Technology, Stanford University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Boston Children's Hospital, Boston, MA, USA

Related conditions & keywords

Spinal Muscular Atrophy Type 3Duchenne Muscular Dystrophy (DMD)SMAspinal muscular atrophyduchenne muscular dystrophyDMDinstrumented insoleneuromuscular diseasemachine learning modelgait analysisfunctional biomarkerwearablesix minute walk testambulatory

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced Apr 9, 2026 · Source of record for eligibility and locations

📊
1 of 106 participants interested
1% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

RECRUITING

Palo Alto

California

Location available
RECRUITING

Boston

Massachusetts

Location available
RECRUITING

New York

New York

Location available

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Find More Pulmonary Embolism Trials by City

Browse all pulmonary embolism clinical trials in these cities — not just this study.

Looking for Spinal Muscular Atrophy Type 3 Treatment in Palo Alto?

Join others in California exploring innovative treatment options through clinical research

Spinal Muscular Atrophy Type 3 Treatment Options in Palo Alto, California

If you're searching for Spinal Muscular Atrophy Type 3 treatment in Palo Alto, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Palo Alto, Boston, New York and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Spinal Muscular Atrophy Type 3. All study-related care is provided at no cost to participants.

Local Sites
3 locations in California
Now Enrolling
Up to 106 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Spinal Muscular Atrophy Type 3?

Potential Benefits

  • Access to new treatment approaches before public availability
  • Close monitoring by experienced medical professionals
  • Study-related care provided at no cost
  • Contribute to medical research for Spinal Muscular Atrophy Type 3

What to Expect

  • Initial screening to determine eligibility
  • Regular check-ups and monitoring visits
  • Possible compensation for time and travel
  • You can withdraw at any time

Frequently Asked Questions About This Spinal Muscular Atrophy Type 3 Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06839469. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.